Drugs for dementia should receive accelerated approval, says world envoyBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g4166 (Published 20 June 2014) Cite this as: BMJ 2014;348:g4166
- Matthew Limb
The drug industry must share data openly as part of a radical new “deal” to expand research in neuroscience and deliver new treatments for dementia, the world dementia envoy, Dennis Gillings, has said. He said that in return it should be made easier for drug companies to invest in antidementia drugs by freeing up regulation and speeding up the clinical trials process.
Gillings said, “I am convinced we must fire up a radical package of measures to achieve the ambition of disease modification and cure.
“The stakes could not be higher: dementia is a ticking bomb costing the global economy $600bn [£350bn; €440bn] and yet progress with research is achingly slow.”
Gillings was speaking in London on 19 June at the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial